XML 154 R105.htm IDEA: XBRL DOCUMENT v3.21.1

Issued Capital and Reserves - Additional Information (Details) € / shares in Units, $ / shares in Units, € in Thousands																		1 Months Ended	12 Months Ended
	Sep. 08, 2020 EUR (€) shares	Aug. 27, 2020 EUR (€)	Aug. 27, 2020 USD ($) $ / shares shares	Jul. 27, 2020 EUR (€)	Jul. 27, 2020 USD ($) $ / shares shares	Jun. 29, 2020 EUR (€)	May 08, 2020 EUR (€) shares	May 05, 2020 EUR (€) shares	Apr. 23, 2020 EUR (€)	Mar. 17, 2020 EUR (€)	Mar. 17, 2020 USD ($)	Mar. 16, 2020 EUR (€) shares	Mar. 16, 2020 USD ($) shares	Nov. 06, 2019 EUR (€)	Nov. 06, 2019 USD ($)	Sep. 18, 2019 shares	Mar. 14, 2019 EUR (€) € / shares shares	Jan. 31, 2019 EUR (€) shares	Dec. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2020 USD ($)	Dec. 31, 2019 EUR (€) € / shares shares	Nov. 30, 2020 USD ($)	Nov. 06, 2019 $ / shares	Oct. 10, 2019 EUR (€)	Oct. 10, 2019 $ / shares	Sep. 26, 2019 EUR (€) shares	Dec. 31, 2018 EUR (€)
Disclosure Of Classes Of Share Capital [Line Items]
Stock split ratio																0.05556
Shares issued during period stock split | shares																206,595,492
Nominal value | € / shares																			€ 1.00		€ 1.00
Equity transaction costs																			€ 33,223		€ 16,638
Shares issued | shares																		5,088,204
Cash investment																											€ 80,000
Share capital																			246,310		232,304
Bill & Melinda Gates Foundation
Disclosure Of Classes Of Share Capital [Line Items]
Share capital																										€ 3,000
Ordinary shares issued | shares																										3,038,674
Ordinary Shares Series B
Disclosure Of Classes Of Share Capital [Line Items]
Share capital																					€ 12,500
Ordinary shares issued | shares																					12,465,288
Ordinary Shares Series B | HONG KONG
Disclosure Of Classes Of Share Capital [Line Items]
Ordinary shares issued but not fully paid | shares																					5,524,506
Global Offering
Disclosure Of Classes Of Share Capital [Line Items]
Aggregate proceeds from issuance of ordinary share																			436,300	$ 513,000,000
Shares issued | shares			16,124		5,500,000
Percentage of ADS to ordinary shares		100.00%	100.00%	100.00%	100.00%
Ordinary shares issued price per share | $ / shares			$ 93.00		$ 93.00
June 2020 Private Placement
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued | shares	2,595,996
Equity issuable						€ 123,900
June 2020 Private Placement | Convertible Note
Disclosure Of Classes Of Share Capital [Line Items]
Maturity period	4 years
At-The-Market Offering Program
Disclosure Of Classes Of Share Capital [Line Items]
Aggregate proceeds from issuance of ordinary share																			€ 76,500	$ 92,900,000
Shares issued | shares																			735,490
Percentage of ADS to ordinary shares																			100.00%	100.00%
Maximum gross proceeds receivable from issuance of ordinary shares | $																						$ 500,000,000
Initial Public Offering (IPO)
Disclosure Of Classes Of Share Capital [Line Items]
Aggregate proceeds from issuance of ordinary share														€ 143,300	$ 157,800,000
Ordinary shares issued price per share | $ / shares																							$ 15.00		$ 15.00
Increase in share capital														10,500
Neon Therapeutics, Inc.
Disclosure Of Classes Of Share Capital [Line Items]
Shares issued | shares							1,935,488
BioNTech Cell & Gene Therapies GmbH
Disclosure Of Classes Of Share Capital [Line Items]
Nominal value | € / shares																	€ 1.00
Shares issued | shares																	2,374,794
Remaining non-controlling interests acquired																	5.50%
Derecognition of non-controlling interest																	€ 700
Decrease in capital reserve																	1,600
Shanghai Fosun Pharmaceuticals (Group) Co., Ltd
Disclosure Of Classes Of Share Capital [Line Items]
Aggregate proceeds from issuance of ordinary share												€ 45,600	$ 50,000,000
Number of ordinary shares issuable | shares												1,580,777	1,580,777
Pfizer Inc.
Disclosure Of Classes Of Share Capital [Line Items]
Aggregate proceeds from issuance of ordinary share										€ 103,900	$ 113,000,000
Shares issued | shares								2,377,446
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital																		€ 5,100	€ 14,000		€ 39,000
Share Capital | Global Offering
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital		€ 16	$ 19,000	€ 5,500	$ 6,400,000														5,500
Share Capital | June 2020 Private Placement
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital						€ 2,600
Share Capital | Initial Public Offering (IPO)
Disclosure Of Classes Of Share Capital [Line Items]
Share capital														500										€ 10,000
Share Capital | Neon Therapeutics, Inc.
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital							€ 1,900
Share Capital | BioNTech Cell & Gene Therapies GmbH
Disclosure Of Classes Of Share Capital [Line Items]
Share capital																	€ 2,400
Share Capital | Shanghai Fosun Pharmaceuticals (Group) Co., Ltd
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital									€ 1,600
Share Capital | Pfizer Inc.
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital								€ 2,400
Treasury Shares
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital																			700
Treasury Shares | At-The-Market Offering Program
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital																			€ 700
Shares issued | shares																			(735,490)
Capital Reserve
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital																			€ 861,000		359,200
Equity transaction costs																			33,223		16,638
Capital Reserve | Bill & Melinda Gates Foundation
Disclosure Of Classes Of Share Capital [Line Items]
Share capital																										€ 46,800
Capital Reserve | Ordinary Shares Series B
Disclosure Of Classes Of Share Capital [Line Items]
Share capital																					€ 186,100
Capital Reserve | Global Offering
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital																			430,800
Capital Reserve | June 2020 Private Placement
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital	€ 121,300
Capital Reserve | At-The-Market Offering Program
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital																			€ 75,800
Capital Reserve | Initial Public Offering (IPO)
Disclosure Of Classes Of Share Capital [Line Items]
Share capital														€ 132,700
Capital Reserve | Neon Therapeutics, Inc.
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital							€ 87,600
Capital Reserve | Shanghai Fosun Pharmaceuticals (Group) Co., Ltd
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital									€ 44,000
Capital Reserve | Pfizer Inc.
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of share capital								€ 101,500

X

- Definition

Cash investment.

+ References

No definition available.

+ Details

Name:	bntx_CashInvestment
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Decrease in capital reserve.

+ References

No definition available.

+ Details

Name:	bntx_DecreaseInCapitalReserve
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Derecognition of non controlling interest.

+ References

No definition available.

+ Details

Name:	bntx_DerecognitionOfNonControllingInterest
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Equity issuable.

+ References

No definition available.

+ Details

Name:	bntx_EquityIssuable
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Financial liability, maturity term.

+ References

No definition available.

+ Details

Name:	bntx_FinancialLiabilityMaturityTerm
Namespace Prefix:	bntx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Maximum proceeds receivable from issuance of ordinary shares.

+ References

No definition available.

+ Details

Name:	bntx_MaximumProceedsReceivableFromIssuanceOfOrdinaryShares
Namespace Prefix:	bntx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Number of ordinary shares issuable.

+ References

No definition available.

+ Details

Name:	bntx_NumberOfOrdinarySharesIssuable
Namespace Prefix:	bntx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of American depository shares to ordinary shares.

+ References

No definition available.

+ Details

Name:	bntx_PercentageOfAmericanDepositorySharesToOrdinaryShares
Namespace Prefix:	bntx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Acquisition of non-controlling interest.

+ References

No definition available.

+ Details

Name:	bntx_RemainingNoncontrollingInterestsAcquiredPercentage
Namespace Prefix:	bntx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Shares issued during period stock split.

+ References

No definition available.

+ Details

Name:	bntx_SharesIssuedDuringPeriodStockSplit
Namespace Prefix:	bntx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Shares issued price per share 1.

+ References

No definition available.

+ Details

Name:	bntx_SharesIssuedPricePerShare1
Namespace Prefix:	bntx_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Stock split conversion ratio.

+ References

No definition available.

+ Details

Name:	bntx_StockSplitConversionRatio
Namespace Prefix:	bntx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The increase (decrease) in equity. [Refer: Equity]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ChangesInEquity
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfClassesOfShareCapitalLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The increase in equity through the issue of equity instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_iii&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_IssueOfEquity
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The nominal value of capital issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 78
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_IssuedCapital
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The number of shares issued by the entity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NumberOfSharesIssued
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The number of shares issued by the entity, for which full payment has been received.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 79
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_ii&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NumberOfSharesIssuedAndFullyPaid
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The number of shares issued by the entity, for which full payment has not been received.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 79
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_ii&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_NumberOfSharesIssuedButNotFullyPaid
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The nominal value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 79
-Subparagraph a
-Clause iii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iii&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ParValuePerShare
Namespace Prefix:	ifrs-full_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 7
-IssueDate 2020-01-01
-Paragraph 17
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ProceedsFromIssueOfOrdinaryShares
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of cost related to the issuance of shares.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard
-URIDate 2020-01-01

+ Details

Name:	ifrs-full_ShareIssueRelatedCost
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	ifrs-full_SignificantInvestmentsInAssociatesAxis=bntx_BillAndMeLindaGatesFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ClassesOfShareCapitalAxis=bntx_OrdinarySharesSeriesBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_HK
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_CapitalRequirementsAxis=bntx_GlobalOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_CapitalRequirementsAxis=bntx_June2020PrivatePlacementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ClassesOfLiabilitiesAxis=bntx_ConvertibleNoteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_CapitalRequirementsAxis=bntx_AtMarketOfferingProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_CapitalRequirementsAxis=bntx_InitialPublicOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=bntx_NeonTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_BusinessCombinationsAxis=bntx_BioNTechCellAndGeneTherapiesGmbHMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bntx_ShanghaiFosunPharmaceuticalGroupCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=bntx_PfizerIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=ifrs-full_TreasurySharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ComponentsOfEquityAxis=ifrs-full_CapitalReserveMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: